Edwards Lifesciences Corporation Securities Lawsuit Investigation

Shamis & Gentile P.A., a law firm that advocates for investors who are victims of securities fraud, is investigating potential claims against Edwards Lifesciences Corporation (EW).

If you purchased or acquired Edwards Lifesciences securities since at least February 2024, and still hold shares today, you may be able to seek corporate reforms, return of funds back to the company, and a court-approved incentive reward, at no cost to you.

About Edwards Lifesciences

Edwards Lifesciences Corporation, headquartered in Irvine, CA, is a medical technology company focused on innovations for structural heart disease and critical care monitoring. The company is known for its transcatheter aortic valve replacement (TAVR) procedures, which are used to treat patients with heart valve disease.

What's Being Investigated

The investigation focuses on allegations that Edwards Lifesciences and certain executives may have misled investors about the Company’s growth prospects and demand for its TAVR procedures. According to a class action complaint, management allegedly created an overly optimistic picture of TAVR revenue growth while failing to disclose that patient activation efforts were underperforming, hospital workflow challenges were limiting procedure volumes, and competing therapies were constraining market expansion.

Shareholders claim the Company’s public statements gave investors the false impression that Edwards was insulated from macroeconomic and capacity-related pressures. These alleged omissions reportedly overstated the strength of the TAVR business and the Company’s ability to sustain double-digit growth.

Key Timeline

• February 6, 2024: Investors allege management’s statements about TAVR demand and patient activation initiatives overstated the Company’s visibility into growth.
• July 24, 2024: Edwards Lifesciences announces lower-than-expected Q2 results and reduces TAVR revenue guidance. Investors allege this served as a corrective disclosure revealing previously concealed risks.
• July 25, 2024: The Company’s stock price falls 31%, from $86.95 to $59.70 per share, erasing billions in market value.

Why Shareholders May be Concerned

Investors and stockholders allege that Edwards’ leadership may have:

• Overstated TAVR growth and market resilience while underplaying competition from newer heart therapies.
• Failed to disclose hospital capacity issues and patient-activation shortfalls that limited revenue growth.
• Lacked adequate internal controls and oversight related to forecasting and risk management.

These allegations raise concerns about board oversight, disclosure accuracy, and governance practices at Edwards Lifesciences.

Your Rights and Next Steps

This investigation concerns potential breaches of duty and oversight failures by certain Edwards Lifesciences directors and officers. Shareholders who have held their stock continuously since February 2024 may have important rights.

Potential Next Steps For Shareholders:

• Act on behalf of the Company: Shareholders may pursue claims alleging failures in oversight and governance.
• Seek corporate reforms: These actions aim to recover funds for the Company and strengthen internal controls.
• Provide documentation: Shareholders may be asked to verify holdings or assist counsel in evaluating potential claims.

You May Have Important Shareholder Rights

If you have held Edwards Lifesciences Corporation (NYSE: EW) shares continuously since at least February 2024, you may have the right to help the Company recover losses, pursue governance reforms, and seek a court-approved incentive award for your participation, all at no cost to you.

To participate, please complete the form below to join the investigation.